A method for preparing energy-saving and environmentally friendly enoxaparin sodium

By simplifying the preparation process of enoxaparin sodium, β elimination and decolorization are directly completed in the degradation and decolorization purification steps, eliminating the use of organic reagents, achieving high yield and high-quality preparation of enoxaparin sodium, solving the problem of current There are many processes and low yields in the process, which are suitable for industrial production.

CN117946294BActive Publication Date: 2024-11-19HEBEI CHANGSHAN KAIKUD BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311505389.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-11-13
Publication Date
2024-11-19
Estimated Expiration
2043-11-13

AI Technical Summary

Technical Problem

The existing enoxaparin sodium preparation process has many processes, large amounts of organic reagents and low yields, which affects the product quality and the feasibility of industrial production.

Method used

After salting and esterification, the sodium heparin raw material is directly degraded and decolorized and purification reactions are carried out. Enoxaparin sodium is obtained through ultrafiltration and lyophilization, eliminating the steps of adding sodium chloride and organic reagents, and simplifying the process flow. .

Benefits of technology

The preparation of enoxaparin sodium with a high yield (over 72%) has been achieved, which reduces organic solvent residues, reduces production costs and environmental pollution, is suitable for industrial applications, and the product quality meets or exceeds the pharmacopoeia standards.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117946294B_ABST
    Figure CN117946294B_ABST
Patent Text Reader

Abstract

The present invention relates to the field of pharmaceutical biotechnology, and proposes a method for preparing energy-saving and environmentally friendly enoxaparin sodium, comprising the following steps: S1, preparation of glycosaminoglycan salt; S2, preparation of glycosaminoglycan ester; S3, preparation of enoxaparin solution; S4, freeze-drying. After the heparin is prepared through salt and ester, β elimination and decolorization are achieved for the first time in the degradation process, and the solution is directly purified by ultrafiltration to obtain enoxaparin sodium solution. After the degradation process is completed, it is directly freeze-dried to obtain enoxaparin sodium raw material. The enoxaparin sodium product prepared by the method has a short process route and a high product yield, and eliminates the use of a large amount of sodium chloride, ethanol and methanol. The product has almost no solvent residues such as methanol or ethanol, and is highly environmentally friendly. Through the above technical scheme, the problems of many preparation process steps of enoxaparin sodium, large amount of organic reagents used, high solvent residues, and low yield of enoxaparin sodium in the related technology are solved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical biotechnology, and in particular to a method for preparing energy-saving and environment-friendly enoxaparin sodium. Background Art

[0002] Heparin is a glycosaminoglycan composed of uronic acid, aminohexose, and their derivatives, with an average molecular weight of 16,000 Da. Low molecular weight heparin is typically produced by chemical degradation of heparin, with an average molecular weight of 4,000-6,500 Da. Enoxaparin sodium is a low molecular weight heparin with an average weight of 3,800-5,000 Da, primarily used to prevent venous thromboembolic disease and thrombosis during extracorporeal hemodialysis, particularly thrombosis associated with orthopedic or general surgery.

[0003] Patent CN103554305B discloses a method for preparing enoxaparin using an affinity precipitation medium. Heparin benzyl ester is degraded with sodium hydroxide in a high-temperature water bath, the pH is adjusted, filtered, and precipitated and graded with 2-4 times ethanol to obtain crude enoxaparin sodium. After drying, the crude product is redissolved and oxidized with hydrogen peroxide at a temperature of 25-30°C and a pH of 8.5-10.5. Upon completion of oxidation, sodium chloride is added and precipitation is performed with 2-3 times ethanol. Patent CN100582123C discloses enoxaparin and its preparation method. Heparin benzyl ester is degraded in a high-temperature aqueous sodium hydroxide solution, cooled to room temperature, and the pH is adjusted to neutral with dilute hydrochloric acid. 15% sodium chloride is added and precipitation is performed with 2 times the amount of methanol. The crude enoxaparin product is dried and redissolved. Oxidation is performed at a temperature of 30-55°C and a pH of 8.0-11.0. Upon completion of oxidation, the solution is adjusted to neutral, 10% sodium chloride is added, and precipitation is performed with 2 times the amount of methanol. Patent CN102603925B discloses a method for directly producing enoxaparin sodium from crude heparin sodium. Heparin benzyl ester is degraded with sodium hydroxide at high temperature, the pH is adjusted to neutral, and 2-3 times ethanol is added for precipitation and fractionation. The precipitate is separated to obtain crude enoxaparin sodium. The crude enoxaparin sodium is dissolved in water, and free sulfate in the solution is adsorbed by a resin. Hydrogen peroxide is then added, and 2 times ethanol is added for further fractionation and precipitation.

[0004] In the preparation technology of above-mentioned enoxaparin sodium, after the degradation step and the oxidation step end, it is necessary to add a large amount of sodium chloride to assist precipitation, which introduces a large amount of foreign impurities and affects the ionization equilibrium of heparin itself. Then, an organic reagent of at least 2 times the amount of solution volume is added to carry out graded precipitation. The use of a large amount of organic reagents increases production cost and subsequent waste liquid post-processing process. Wherein the degradation step and the oxidation step are carried out step by step, and then the intermediate enoxaparin sodium crude product also needs to be dried and processed, and the oxidation step processing conditions are harsh, which ultimately causes the enoxaparin sodium yield to be lower and is unfavorable for industrialized production. Therefore, it is crucial to prepare a method for enoxaparin sodium with high yield. Summary of the Invention

[0005] The present invention provides an energy-saving and environmentally friendly preparation method of enoxaparin sodium, which solves the problems in the related art of enoxaparin sodium preparation process of multiple steps, large amount of organic reagents used and low enoxaparin sodium yield.

[0006] The technical solutions of the present invention are as follows:

[0007] The present invention provides an energy-saving and environmentally friendly method for preparing enoxaparin sodium, comprising the following steps:

[0008] S1. Dissolving the heparin sodium raw material in water, and adding benzethonium chloride solution to prepare a glycosaminoglycan salt;

[0009] S2, dissolving the glycosaminoglycan salt in N,N-dimethylformamide, adding benzyl chloride, reacting, adding sodium acetate ethanol solution for precipitation, washing and drying the precipitate to obtain a glycosaminoglycan ester;

[0010] S3, dissolving the glycosaminoglycan ester in water, adding a degradation agent to perform degradation reaction at 50-60° C., adding an oxidant to perform decolorization and purification, adjusting the pH to 6.5-7.0, filtering, and ultrafiltration to obtain an enoxaparin sodium solution;

[0011] S4. Sterilize the enoxaparin sodium solution and freeze-dry it to obtain enoxaparin sodium.

[0012] As a further technical solution, the degradation agent includes sodium hydroxide and / or sodium carbonate, and the oxidant includes hydrogen peroxide and / or peracetic acid.

[0013] As a further technical solution, the raw material of heparin sodium includes porcine mucosal heparin or sheep mucosal heparin.

[0014] As a further technical solution, the mass volume ratio of the glycosaminoglycan salt to N,N-dimethylformamide is 1:5~10g / mL.

[0015] As a further technical solution, the mass volume ratio of the glycosaminoglycan salt to benzyl chloride is 1:0.2~2g / mL.

[0016] As a further technical solution, in step S2, the reaction temperature is 30-45° C., and the reaction time is 5-24 h.

[0017] As a further technical solution, the mass concentration of the sodium acetate ethanol solution is 8% to 10%.

[0018] As a further technical solution, in step S3, the degradation reaction time is 1 to 3 hours; and the decolorization and purification time is 3 to 6 hours.

[0019] As a further technical solution, the mass ratio of the glycosaminoglycan ester to the degradation agent is 1:0.05~0.1.

[0020] As a further technical solution, the added volume of the oxidant is 0.3% to 1.0% of the volume of the degradation solution obtained by the degradation reaction.

[0021] As a further technical solution, in step S3, ultrafiltration is performed using a 1KD ultrafiltration membrane, the amount of water replenished during the ultrafiltration process is 1 to 2 times the volume of the solution, and the volume of the enoxaparin sodium solution is 1 / 3 to 1 / 2 of the volume of the drug solution before ultrafiltration.

[0022] The working principle and beneficial effects of the present invention are:

[0023] 1. In the present invention, the heparin sodium raw material is sequentially salified and esterified before entering the degradation process. No sodium chloride and organic reagents need to be added for graded precipitation in the degradation process and the decolorization and purification process. For the first time, β elimination and decolorization are completed during the degradation process. The decolorized and purified solution is directly purified by ultrafiltration and freeze-dried to obtain enoxaparin sodium, eliminating the use of a large amount of sodium chloride, ethanol and methanol. The product has almost no residual solvents such as methanol or ethanol, is highly environmentally friendly, and does not require the subsequent treatment of organic waste liquid, waste methanol and waste ethanol. There are no explosion-proof requirements for the production process, and no special protection needs for operators.

[0024] 2. In the present invention, there is no need to control temperature and pH during the decolorization and purification process, the equipment requirements are low, the application range is wide, and it is suitable for industrial application.

[0025] 3. In the present invention, the process route for producing enoxaparin sodium is short, the intermediate control is precise, and there is no need for repeated operation to adjust the control indicators. The quality of the prepared enoxaparin sodium product is far superior to the current enoxaparin sodium CP / EP / USP pharmacopoeia standards, and the yield is as high as 72% or more.

[0026] 4. In the present invention, porcine mucosal heparin and sheep mucosal heparin are used as raw materials for heparin sodium, which expands the source of starting raw materials. At the same time, sheep mucosal heparin is used as the starting raw material, which effectively utilizes sheep intestine resources and is suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] The present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments.

[0028] Figure 1 This is a process flow chart of Example 1 of the present invention. DETAILED DESCRIPTION

[0029] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the embodiments described are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making any creative efforts are within the scope of protection of the present invention.

[0030] Example 1

[0031] S1. Preparation of glycosaminoglycan salts

[0032] Take 100 g of porcine heparin sodium and add it to 1000 mL of purified water and stir to dissolve it. Take another 250 g of benzethonium chloride and add it to 1500 mL of purified water and dissolve it. Mix them, stir and react for 2 hours, filter and dry to obtain 305 g of glycosaminoglycan salt.

[0033] S2. Preparation of glycosaminoglycan esters

[0034] The glycosaminoglycan salt obtained above was added to 2.4 L of N, N-dimethylformamide and stirred to dissolve. 180 mL of benzyl chloride was added and the reaction was stirred at 39-41 ° C for 8 h before stopping. 7.7 L of 8 wt% sodium acetate ethanol solution was added for precipitation. The obtained precipitate was washed with ethanol, dehydrated, and dried to prepare 103 g of glycosaminoglycan ester.

[0035] S3. Preparation of Enoxaparin Solution

[0036] The glycosaminoglycan ester obtained above was added to 2L of purified water and stirred to dissolve, the temperature was raised to 50-60°C, 7.8g of sodium hydroxide was added for degradation, the temperature was controlled at 57-59°C, and the temperature control was stopped after the reaction for 1.5h. 12mL of hydrogen peroxide was added and the stirring was continued for 4.5h. The pH was adjusted to 6.8 and filtered. The filtrate was ultrafiltered using a 1KD ultrafiltration membrane, and 3L of water was added during the period. The filtrate was ultrafiltered to 800mL and stopped to obtain enoxaparin sodium solution.

[0037] S4. Freeze-drying

[0038] The above enoxaparin sodium solution was passed through a 0.2 μm filter and then freeze-dried to obtain 72.5 g of sheep-derived enoxaparin sodium fine product, with a weight yield of 72.5%.

[0039] Example 2

[0040] S1. Preparation of glycosaminoglycan salts

[0041] 2 kg of sheep-derived heparin sodium was added to 20 L of purified water and stirred to dissolve. 5.6 kg of benzethonium chloride was added to 30 L of purified water and dissolved. The mixture was mixed and stirred to react for 2 h. The mixture was filtered and dried to obtain 6.081 kg of glycosaminoglycan salt.

[0042] S2. Preparation of glycosaminoglycan esters

[0043] The glycosaminoglycan salt obtained above was added to 30 L of N, N-dimethylformamide and stirred to dissolve. 6 L of benzyl chloride was added and the reaction was stirred at 34-36 ° C for 20 h before stopping. 90 L of 8 wt% sodium acetate ethanol solution was added for precipitation. The obtained precipitate was washed with ethanol, dehydrated, and dried to prepare 2.012 kg of glycosaminoglycan ester.

[0044] S3. Preparation of Enoxaparin Solution

[0045] The glycosaminoglycan ester obtained above was added to 40 L of purified water and stirred to dissolve, the temperature was raised to 50-60 ° C, 144 g of sodium hydroxide was added for degradation, the temperature was controlled at 55-57 ° C, and the temperature control was stopped after the reaction for 2 h. 160 mL of hydrogen peroxide was added and the stirring was continued for 4 h. The pH was adjusted to 6.8 and filtered. The filtrate was ultrafiltered using a 1KD ultrafiltration membrane, 50 L of water was added during the period, and the filtrate was ultrafiltered to 15 L to obtain enoxaparin sodium solution.

[0046] S4. Freeze-drying

[0047] The enoxaparin sodium solution was passed through a 0.2 μm filter cartridge and then freeze-dried to obtain 1.460 kg of enoxaparin sodium fine product, with a weight yield of 73%.

[0048] Example 3

[0049] S1. Preparation of glycosaminoglycan salts

[0050] 2 kg of sheep-derived heparin sodium was added to 20 L of purified water and stirred to dissolve. 5.6 kg of benzethonium chloride was added to 30 L of purified water and dissolved. The mixture was mixed and stirred to react for 2 h. The mixture was filtered and dried to obtain 6.108 kg of glycosaminoglycan salt.

[0051] S2. Preparation of glycosaminoglycan esters

[0052] The glycosaminoglycan salt obtained above was added to 60 L of N, N-dimethylformamide and stirred to dissolve. 1.3 L of benzyl chloride was added and the reaction was stirred at 43-45 ° C for 5 h before stopping. 90 L of 8 wt% sodium acetate ethanol solution was added for precipitation. The obtained precipitate was washed with ethanol, dehydrated, and dried to prepare 2.095 kg of glycosaminoglycan ester.

[0053] S3. Preparation of Enoxaparin Solution

[0054] The glycosaminoglycan ester obtained above was added to 40 L of purified water and stirred to dissolve, the temperature was raised to 50-60 ° C, 200 g of sodium carbonate was added for degradation, the temperature was controlled at 51-53 ° C, and the temperature control was stopped after the reaction for 3 h. 400 mL of peracetic acid was added and the stirring was continued for 3 h 10 min. The pH was adjusted to 6.8 and filtered. The filtrate was ultrafiltered using a 1KD ultrafiltration membrane, during which 80 L of water was added. The filtrate was ultrafiltered to 20 L and stopped to obtain enoxaparin sodium solution.

[0055] S4. Freeze-drying

[0056] The above enoxaparin sodium solution was passed through a 0.2 μm filter cartridge and then freeze-dried to obtain 1.456 kg of enoxaparin sodium fine product, with a weight yield of 72.8%.

[0057] Example 4

[0058] S1. Preparation of glycosaminoglycan salts

[0059] 2 kg of sheep-derived heparin sodium was added to 20 L of purified water and stirred to dissolve. 5.6 kg of benzethonium chloride was added to 30 L of purified water and dissolved. The mixture was mixed and stirred to react for 2 h. The mixture was filtered and dried to obtain 6.019 kg of glycosaminoglycan salt.

[0060] S2. Preparation of glycosaminoglycan esters

[0061] The glycosaminoglycan salt obtained above was added to 48 L of N, N-dimethylformamide and stirred to dissolve. 12 L of benzyl chloride was added and the reaction was stirred at 30-32 ° C for 24 h before stopping. 90 L of 8 wt% sodium acetate ethanol solution was added for precipitation. The obtained precipitate was washed with ethanol, dehydrated, and dried to prepare 2.069 kg of glycosaminoglycan ester.

[0062] S3. Preparation of Enoxaparin Solution

[0063] The glycosaminoglycan ester obtained above was added to 40 L of purified water and stirred to dissolve, the temperature was raised to 50-60 ° C, 105 g of sodium hydroxide was added for degradation, the temperature was controlled at 54-56 ° C, and the temperature control was stopped after the reaction for 1 hour. 120 mL of hydrogen peroxide was added and the stirring was continued for 5 hours and 50 minutes. The pH was adjusted to 6.8 and filtered. The filtrate was ultrafiltered using a 1KD ultrafiltration membrane, during which 40 L of water was added. The filtrate was ultrafiltered to 14 L and then stopped to obtain enoxaparin sodium solution.

[0064] S4. Freeze-drying

[0065] The above enoxaparin sodium solution was passed through a 0.2 μm filter cartridge and then freeze-dried to obtain 1.511 kg of enoxaparin sodium fine product, with a weight yield of 75.6%.

[0066] The enoxaparin sodium fine product prepared in Examples 1 to 4 was tested for 1,6-anhydro derivatives, molecular weight and distribution, potency, ethanol, and methanol according to the European Pharmacopoeia EP10.5. The test results are shown in Table 1:

[0067] Table 1 Test results of the enoxaparin sodium products prepared in Examples 1 to 4

[0068]

[0069] It can be seen from the data of Examples 1 to 4 in Table 1 that the enoxaparin sodium fine product prepared by the present invention meets the enoxaparin sodium CP / EP / USP pharmacopoeia standards and has a quality far higher than the current pharmacopoeia standards, with a yield of more than 72%, and the ethanol and methanol contents are far lower than the current CP / EP / USP pharmacopoeia standards.

[0070] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A method for preparing energy-saving and environmentally friendly enoxaparin sodium, characterized in that: The following steps are involved: S1. Dissolving the heparin sodium raw material in water, and adding benzethonium chloride solution to prepare glycosaminoglycan salt; S2, adding the glycosaminoglycan salt to N,N-dimethylformamide to dissolve, adding benzyl chloride to react, adding sodium acetate ethanol solution to precipitate, washing and drying the precipitate to obtain glycosaminoglycan ester; S3, dissolving the glycosaminoglycan ester in water, adding a degradation agent to perform a degradation reaction at 50-60° C., adding an oxidant to perform decolorization and purification, adjusting the pH to 6.5-7.0, filtering, and ultrafiltration to obtain an enoxaparin sodium solution; S4, sterilizing the enoxaparin sodium solution, and freeze-drying to obtain enoxaparin sodium; In the degradation process and the decolorization and purification process, there is no need to add sodium chloride and organic reagents for graded precipitation; The raw material of heparin sodium includes porcine mucosal heparin or sheep mucosal heparin; The mass volume ratio of the glycosaminoglycan salt to N,N-dimethylformamide is 1:5-10 g / mL; The mass volume ratio of the glycosaminoglycan salt to benzyl chloride is 1:0.2~2g / mL; In step S2, the reaction temperature is 30-45°C and the reaction time is 5-24h; The mass concentration of the sodium acetate ethanol solution is 8% to 10%; In step S3, the degradation reaction time is 1 to 3 hours; the decolorization and purification time is 3 to 6 hours; The mass ratio of the glycosaminoglycan ester to the degradation agent is 1:0.05-0.1; The added volume of the oxidant is 0.3% to 1.0% of the volume of the degradation solution obtained by the degradation reaction; In step S3, the ultrafiltration is performed using a 1KD ultrafiltration membrane, the amount of water replenished during the ultrafiltration process is 1 to 2 times the volume of the solution, and the volume of the enoxaparin sodium solution is 1 / 3 to 1 / 2 of the volume of the drug solution before ultrafiltration.